Several researches identified the prognostic significance of DLX4 in patients with colorectal cancer (Hollington et al., 2004), breast cancer (Yu et al., 2008a), non-small cell lung cancer (Yu et al., 2008b), prostate adenocarcinoma (Schwartz et al., 2009), hepatocellular carcinoma (Xie et al., 2015), ovarian cancer (Haria et al., 2015), chronic myeloid leukemia (Zhou et al., 2015), acute myeloid leukemia (Zhou et al., 2016), and endometrial cancer (Zhang et al., 2019). Here, DLX4 is linked to ovarian carcinoma.